Fintel reports that on January 21, 2026, Chardan Capital initiated coverage of Alumis (NasdaqGS:ALMS) with a Buy recommendation. Analyst Price Forecast Suggests 39.23% Upside As of January 14, 2026, ...

Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co. lifted its ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alan Colowick, a director at $ALMS, bought 16,104 shares of the company on 04-01-2025 for an estimated $112,309. This trade was reported by Quiver Quantitative using ...

On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ:ALMS) with an Overweight rating and a $23 price target after the company’s recent merger with Acelyrin and its Q1 2025 earnings ...

Foresite Capital Fund VI, L.P. holds 4,247,670 shares, Labs Co-Invest V, LLC holds 194,459 shares, Foresite Labs Fund I, L.P. holds 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC holds 1,176 ...

None ...